Trophic serves as a strategic partner for all aspects of communications for life science companies. We apply a deep understanding of both the science and business of drug development and the capital needed for success. Based on breadth and depth of experience, Trophic has become the go-to advisory for presenting corporate stories and scientific concepts. Current client portfolio ranges from biotech start-ups, listed biopharmas and small and large pharmaceutical companies.

TROPHIC TWITTER FEED

Follow us on Twitter to stay tuned on biotech news and the inner workings of the Trophic team

Buon compleanno a nostra @WeickertMarie! Why the Italian you ask? Well, how else should we celebrate this sunny birthday than with heavenly pasta from La Certosa?
Also:
Oiss Guade zum Burzeldog. Willow "Bean" is also thrilled to know 'birthday' in Bayrisch includes the word #dog

Congrats to $POXEL on the positive top-line Phase 3 data from their TIMES 1 trial for the treatment of type 2 #diabetes in Japan. This is a significant milestone for Poxel & their lead drug candidate, Imeglimin. See here for full announcement: https://t.co/TxbATv324E

Ad hoc news alert: Willow "Bean" Roters to wear #biotech-themed party hat as @VFTrophic joins Trophic as Account Executive. A solid two "cell-ebratory" paws up from Willow & the team! Welcome / Willkommen / Benvenuta, Valeria!

Load More...